ClinicalTrials.gg
CompletedNCT05171348Updated Jun 22, 2023

A Multiple Ascending Doses Study of CM326 Injection in Healthy Subjects

A Phase 1 interventional study of CM326 and Placebo in Asthma, sponsored by Keymed Biosciences Co.Ltd. Completed at 1 site in China. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-06-22.

Sponsored by Keymed Biosciences Co.Ltd · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 251 studies in Asthma with a site in China — 87 open to participants now, 96 under way, 15 of them phase 3. Asthma · China.

Enrollment
154th of 182
40 · median 203
Started
2022
with 20 others
Phase 1
31 of 251
3 open now
Registered
114th of 251
by date

Among the 251 studies in Asthma with a site in China, this one is the 154th largest by enrollment of the 182 interventional ones that give a count, is one of 21 that started in 2022, is one of 31 in phase 1, and was the 114th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

87 of the 251 studies in Asthma with a site in China are open now. Recruiting first, the newest first:

82 more — sign in →

All 87 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 65 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 251 studies in Asthma with a site in China, or all of them as a file.
02

Study summary

This is a single-center, randomized, double-blind, placebo-controlled, dose-escalating study to evaluate the safety, tolerability, PK profile, and immunogenicity of multiple SC administraion of CM326 at different doses in healthy subjects.

40 healthy male subjects will be enrolled in the study. The drug will be administered by dose-escalating principle at 4 dose levels: 55 mg Q2W, 110 mg Q2W, 220 mg Q2W, 220 mg Q4W.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male healthy volunteers, aged between 18 and 65 years of age inclusive, with a (BMI) within 18-26 kg/m2 (inclusive);
  • Medical history, vital signs, physical examination, 12-lead , chest X-ray and abdominal color ultrasound are normal or abnormal with no clinical significance;
  • All variables of clinical laboratory tests are normal or abnormal with no clinical significance;
  • Subjects and partners agree to take effective throughout the study (from screening to 3 months after the end of treatment);
  • Capable of understanding the nature of the study and voluntarily signing the Form.

Exclusion criteria

Exclusion Criteria:

  • Known allergy to monoclonal antibody drugs or other related drugs, or allergy to of CM326 injection;
  • History of any clinically serious disease or history of circulatory, endocrine, neurological or hematological, immune, psychiatric, and metabolic diseases;
  • History of asthma and allergic reactions;
  • Use of any prescription drugs within 2 weeks prior to dosing, use of traditional Chinese medicine or over-the-counter drugs within 1 week prior to dosing;
  • Received any marketed or biologics within 5 half-lives (if known) or 12 weeks (whichever is longer) prior to dosing, or any investigational non-biologics within 5 half-lives (if known) or 4 weeks (whichever is longer) prior to dosing.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    CM326 55mg Q2W

    55mg for 6 doses, SC, Q2W

    Drug: CM326

  • Experimental
    CM326 110mg Q2W

    110mg for 6 doses, SC, Q2W

    Drug: CM326

  • Experimental
    CM326 220mg Q2W

    220mg for 6 doses, SC, Q2W

    Drug: CM326

  • Experimental
    CM326 220mg Q4W

    220mg for 3 doses, SC, Q4W

    Drug: CM326

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

Interventions

  • DrugCM326

    a humanized monoclonal antibody

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events (AEs)

    Incidence of AEs, including any abnormal physical examinations, abnormal vital signs, abnormal ECG, and abnormal lab testing.

    Time frame: up to Week 24

Secondary outcomes

  1. PK parameters: time to maximum concentration (Tmax).

    Time to maximum concentration (Tmax).

    Time frame: up to Week 16

  2. PK parameters: maximum concentration (Cmax).

    Maximum concentration (Cmax).

    Time frame: up to Week 16

  3. PK parameters: area under the plasma concentration-time curve over a dosing interval (AUCtau).

    Area under the plasma concentration-time curve over a dosing interval (AUCtau).

    Time frame: up to Week 16

  4. PK parameters: area under the plasma concentration-time curve from 0 to t (AUC0-t).

    Area under the plasma concentration-time curve from 0 to t (AUC0-t).

    Time frame: up to Week 16

  5. Immunogenicity endpoints: Occurrence of anti-drug antibodies (ADA) to CM326.

    Occurrence of anti-drug antibodies (ADA) to CM326.

    Time frame: up to Week 16

07

Study locations

1 site
  • West China Hospital of Sichuan University
    Chengdu, Sichuan, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2022 to primary completion in Oct 2022, 9 months.

Of 173 industry-sponsored phase 1 interventional studies under Asthma, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 9 months is above that.

Counting every sponsor, half of 200 studies reached it within 6 months; a quarter within 3 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2021
First posted
Dec 28, 2021
StartActual
Jan 7, 2022
Primary completionActual
Oct 11, 2022
CompletionActual
Oct 11, 2022
Last update
Jun 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05171348
Responsible party
Sponsor
First posted
Dec 28, 2021
Start date
Jan 7, 2022
Primary completion
Oct 11, 2022
Completion
Oct 11, 2022
Last update
Jun 22, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ocankitug

Start the discussion